Chimeric Therapeutics Ltd News

Chimeric Therapeutics Ltd: Notice under section 708A

Nov 5 13:24

Chimeric Therapeutics Ltd: Application for quotation of securities - CHM

Nov 5 13:20

Chimeric Therapeutics Ltd: Notice of Extraordinary General Meeting December 2024

Nov 5 05:32

Chimeric Therapeutics Ltd: Quarterly Activities/Appendix 4C Cash Flow Report

Oct 30 11:47

Chimeric Therapeutics Ltd: Investor webinar

Oct 24 13:11

Chimeric Therapeutics Ltd: Dose finding complete in ADVENT-AML Phase 1b clinical trial

Oct 24 06:55

Chimeric Therapeutics Ltd: Application for quotation of securities - CHM

Oct 24 06:54

Chimeric Therapeutics Ltd: Prospectus

Oct 23 05:57

Chimeric Therapeutics Ltd: Reinstatement to Official Quotation

Oct 21 16:01

Chimeric Therapeutics Ltd: ESG Report

Oct 21 12:12

Chimeric Therapeutics Ltd: Corporate Governance Statement and Appendix 4G

Oct 21 12:12

Chimeric Therapeutics Ltd: Annual Report 2024

Oct 21 12:10

Chimeric Therapeutics Ltd: Proposed issue of securities - CHM

Oct 21 08:49

Chimeric Therapeutics Ltd: Proposed issue of securities - CHM

Oct 21 08:49

Chimeric Therapeutics Ltd: $5 million Placement to progress CHM CDH17 trial

Oct 21 08:48

Chimeric Therapeutics Ltd: Change in substantial holding - PH

Oct 16 15:36

Chimeric Therapeutics Ltd: Notice of Annual General Meeting

Oct 14 14:15

Chimeric Therapeutics Ltd: 2024 Annual Report update

Oct 11 13:17

Chimeric Therapeutics Ltd: AML patient achieves Complete Response in CHM CORE-NK trial

Oct 7 06:45

Chimeric Therapeutics Ltd: 2024 Annual Report update

Oct 4 10:05